Department of Defense completes rapid response exercise

AVIBiopharma and the U.S. Department of Defense recently completed 11 days of a rapid response exercise using a potentially fatal pathogen.

The work was supported by the Transformational Medical Technologies program, which is funded by the United States Department of Defense Chemical and Biological Defense program, which is, in turn, supported by the Defense Threat Reduction Agency, according to

The AVI BioPharma tests centered on the appearance of the dengue virus, a sometimes fatal disease that infects up to 100 million people worldwide every year. AviBiopharma conducted its first TMT rapid response exercise successfully using the pandemic in 2009.

The major test in the formal response exercise was to take a dengue vaccine from conception to production in the span of 11 days.

The drug candidate in this case, AVI-6006, uses AVI Biopharma’s proprietary PMOplus technology, which is a positively charged-version of its neutrally-charged phosphorodiamidate morpholino oligomer chemistry, reports.

The exercise was part of an effort by the TMT, partnered with AVI, to conceptualize, develop and refine a rapid response capacity that includes the ability to identify a threat and respond to it by designing and producing a therapeutic candidate and then evaluating its preclinical efficacy.

"AVI's ability to effectively and rapidly respond to real-world infectious disease and biological threats is inherent to the nature of our RNA-based technologies and represents the prospect of a new, faster, more efficient, and perhaps more predictable, option for drug development in our industry," Chris Garabedian, AVI's CEO and president said, according to

Organizations in this story

U.S. Department of Defense 2 N Rotary Rd Arlington, VA 22202

Get notified the next time we write about U.S. Department of Defense!